Regarding cancer, studies have indicated that using FK506, which binds to the FK1 domain of FKBPs, or MJC13, an inhibitor of FKBP52, to treat prostate cancer can inhibit cell proliferation and AR activity [104,105,106]. This evidence concerns the gene FKBP4 and prostate cancer.